A Comprehensive Review and Androgen Deprivation Therapy and Its Impact on Alzheimer’s Disease Risk in Older Men with Prostate Cancer

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. 2018;68(6):394–424. doi:10.3322/caac.21492
   Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA. 2020;70(1):7–30. doi:10.3322/caac.21590
   Web of Science ®Google Scholar
• Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Europ Urol. 2012;61(6):1079–1092. doi:10.1016/j.eururo.2012.02.054
   PubMed Web of Science ®Google Scholar
• Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules. 2022;27(17):5730. doi:10.3390/molecules27175730
   PubMed Web of Science ®Google Scholar
• Rebbeck TR, Devesa SS, Chang BL, et al. Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of African descent. Prostate Cancer. 2013;2013:560857. doi:10.1155/2013/560857
   PubMedGoogle Scholar
• Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer. 2007;121(7):1571–1578. doi:10.1002/ijc.22788
   PubMed Web of Science ®Google Scholar
• Achard V, Putora PM, Omlin A, Zilli T, Fischer S. Metastatic prostate cancer: treatment options. Oncology. 2022;100(1):48–59. doi:10.1159/000519861
   PubMed Web of Science ®Google Scholar
• Rebello RJ, Oing C, Knudsen KE, et al. Prostate cancer. Nature Reviews Disease Primers. 2021;7(1):9. doi:10.1038/s41572-020-00243-0
   PubMed Web of Science ®Google Scholar
• Nead KT, Gaskin G, Chester C, et al. Androgen deprivation therapy and future Alzheimer’s disease risk. J Clin Oncol. 2016;34(6):566. doi:10.1200/JCO.2015.63.6266
   PubMed Web of Science ®Google Scholar
• Kluger J, Roy A, Chao HH. Androgen deprivation therapy and cognitive function in prostate cancer. Current Oncol Rep. 2020;22(3):24. doi:10.1007/s11912-020-0884-1
   PubMed Web of Science ®Google Scholar
• Junejo NN, AlKhateeb SS. BRCA2 gene mutation and prostate cancer risk. Comprehensive review and update. Saudi Med J. 2020;41(1):9–17. doi:10.15537/smj.2020.1.24759
   PubMed Web of Science ®Google Scholar
• Salminen EK, Portin RI, Koskinen A, Helenius H, Nurmi M. Associations between serum testosterone fall and cognitive function in prostate cancer patients. Clin Cancer Res. 2004;10(22):7575–7582. doi:10.1158/1078-0432.CCR-04-0750
   PubMed Web of Science ®Google Scholar
• Dumurgier J, Sabia S. Life expectancy in dementia subtypes: exploring a leading cause of mortality. Lancet Healthy Longevity. 2021;2(8):e449–e450. doi:10.1016/s2666-7568(21)00166-5
   PubMedGoogle Scholar
• Merriel SWD, Funston G, Hamilton W. Prostate Cancer in Primary Care. Adv Ther. 2018;35(9):1285–1294. doi:10.1007/s12325-018-0766-1
   PubMed Web of Science ®Google Scholar
• Driver JA, Beiser A, Au R, et al. Inverse association between cancer and Alzheimer’s disease: results from the Framingham Heart Study. BMJ. 2012;2:344.
   Google Scholar
• Hwang S, Jayadevappa R, Zee J, et al. Concordance between clinical diagnosis and Medicare claims of depression among older primary care patients. Am J Geriatric Psychiatry. 2015;23(7):726–734. doi:10.1016/j.jagp.2014.08.009
   PubMed Web of Science ®Google Scholar
• Bhoir S, De Benedetti A. Targeting prostate cancer, the ‘tousled way’. Int J Mol Sci. 2023;24(13):11100. doi:10.3390/ijms241311100
   PubMed Web of Science ®Google Scholar
• Sari Motlagh R, Quhal F, Mori K, et al. The risk of new onset dementia and/or Alzheimer disease among patients with prostate cancer treated with androgen deprivation therapy: a systematic review and meta-analysis. J Urol. 2021;205(1):60–67. doi:10.1097/ju.0000000000001341
   PubMed Web of Science ®Google Scholar
• Azam MF, Musa A, Dehmer M, Yli-Harja OP, Emmert-Streib F. Global genetics research in prostate cancer: a text mining and computational network theory approach Original Research. Front Gene. 2019;10. doi:10.3389/fgene.2019.00070
   PubMed Web of Science ®Google Scholar
• Chung LW, Baseman A, Assikis V, Zhau HE. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol. 2005;173(1):10–20. doi:10.1097/01.ju.0000141582.15218.10
   PubMed Web of Science ®Google Scholar
• Prensner JR, Chinnaiyan AM. Oncogenic gene fusions in epithelial carcinomas. Curr Opin Genet Dev. 2009;19(1):82–91. doi:10.1016/j.gde.2008.11.008
   PubMed Web of Science ®Google Scholar
• Feinberg AP, Koldobskiy MA, Göndör A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat Rev Genet. 2016;17(5):284–299. doi:10.1038/nrg.2016.13
   PubMed Web of Science ®Google Scholar
• Thomson DW, Shahrin NH, Wang PP, et al. Aberrant RAG-mediated recombination contributes to multiple structural rearrangements in lymphoid blast crisis of chronic myeloid leukemia. Leukemia. 2020;34(8):2051–2063. doi:10.1038/s41375-020-0751-y
   PubMed Web of Science ®Google Scholar
• Vafadar A, Shabaninejad Z, Movahedpour A, et al. Quercetin and cancer: new insights into its therapeutic effects on ovarian cancer cells. Cell Biosci. 2020;10(1):32. doi:10.1186/s13578-020-00397-0
   PubMed Web of Science ®Google Scholar
• Sheffels E, Sealover NE, Theard PL, Kortum RL. Anchorage-independent growth conditions reveal a differential SOS2 dependence for transformation and survival in RAS-mutant cancer cells. Small GTPases. 2021;12(1):67–78. doi:10.1080/21541248.2019.1611168
   PubMedGoogle Scholar
• Ullah R, Yin Q, Snell AH, Wan L. RAF-MEK-ERK Pathway in Cancer Evolution and Treatment. Elsevier; 2022:123–154.
   Google Scholar
• Quintero-Fabián S, Arreola R, Becerril-Villanueva E, et al. Role of matrix metalloproteinases in angiogenesis and cancer. Review. Front Oncol. 2019;2019:9. doi:10.3389/fonc.2019.01370
   Google Scholar
• Rosenwald A, Bens S, Advani R, et al. Prognostic Significance of MYC rearrangement and translocation partner in diffuse large B-Cell lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol. 2019;37(35):3359–3368. doi:10.1200/jco.19.00743
   PubMed Web of Science ®Google Scholar
• Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TLJ, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res. 2007;67(13):6130–6135. doi:10.1158/0008-5472.can-07-0533
   PubMed Web of Science ®Google Scholar
• Shinde P, Marrec L, Rai A, et al. Symmetry in cancer networks identified: proposal for multicancer biomarkers. Network Sci. 2019;7(4):541–555. doi:10.1017/nws.2019.55
   Web of Science ®Google Scholar
• Brown D, Oetzel J, Henderson A. Communication networks of men facing a diagnosis of prostate cancer. J Clin Nurs. 2016;25(21–22):3266–3278. doi:10.1111/jocn.13369
   PubMed Web of Science ®Google Scholar
• Ammah AA, Do DN, Bissonnette N, Gévry N, Ibeagha-Awemu EM. Co-expression network analysis identifies miRNA–mRNA networks potentially regulating milk traits and blood metabolites. Int J Mol Sci. 2018;19(9):2500. doi:10.3390/ijms19092500
   PubMed Web of Science ®Google Scholar
• Bee A, Brewer D, Beesley C, et al. siRNA knockdown of ribosomal protein gene RPL19 abrogates the aggressive phenotype of human prostate cancer. PLoS One. 2011;6(7):e22672. doi:10.1371/journal.pone.0022672
   PubMed Web of Science ®Google Scholar
• Yong WH, Shabihkhani M, Telesca D, et al. Ribosomal proteins RPS11 and RPS20, two stress-response markers of glioblastoma stem cells, are novel predictors of poor prognosis in glioblastoma patients. PLoS One. 2015;10(10):e0141334. doi:10.1371/journal.pone.0141334
   PubMed Web of Science ®Google Scholar
• Dai M-S, Arnold H, Sun -X-X, Sears R, Lu H. Inhibition of c-Myc activity by ribosomal protein L11. EMBO J. 2007;26(14):3332–3345. doi:10.1038/sj.emboj.7601776
   PubMed Web of Science ®Google Scholar
• Meng X, Tackmann NR, Liu S, et al. RPL23 links oncogenic RAS signaling to p53-mediated tumor suppression. Cancer Res. 2016;76(17):5030–5039. doi:10.1158/0008-5472.CAN-15-3420
   PubMed Web of Science ®Google Scholar
• Golomb L, Volarevic S, Oren M. P53 and ribosome biogenesis stress: the essentials. FEBS Lett. 2014;588. doi:10.1016/j.febslet.2014.04.014
   Web of Science ®Google Scholar
• Shao J, Wang L, Zhong C, Qi R, Li Y. AHSA1 regulates proliferation, apoptosis, migration, and invasion of osteosarcoma. Biomed Pharmacother. 2016;77:45–51. doi:10.1016/j.biopha.2015.11.008
   PubMed Web of Science ®Google Scholar
• Qiu N, He Y, Zhang S, Hu X, Chen M, Li H. Cullin 7 is a predictor of poor prognosis in breast cancer patients and is involved in the proliferation and invasion of breast cancer cells by regulating the cell cycle and microtubule stability. Oncol Rep. 2018;39(2):603–610. doi:10.3892/or.2017.6106
   PubMed Web of Science ®Google Scholar
• Tian P, Liu D, Sun L, Sun H. Cullin7 promotes epithelial‑mesenchymal transition of esophageal carcinoma via the ERK‑SNAI2 signaling pathway. Mole Med Rep. 2018;17(4):5362–5367. doi:10.3892/mmr.2018.8503
   PubMed Web of Science ®Google Scholar
• Schipany K, Rosner M, Ionce L, Hengstschläger M, Kovacic B. eIF3 controls cell size independently of S6K1-activity. Oncotarget. 2015;6(27):24361–24375. doi:10.18632/oncotarget.4458
   PubMedGoogle Scholar
• Perlaky L, Valdez BC, Busch RK, et al. Increased growth of NIH/3T3 cells by transfection with human p120 complementary DNA and inhibition by a p120 antisense construct. Cancer Res. 1992;52(2):428–436.
   PubMed Web of Science ®Google Scholar
• Wang M, Wey S, Zhang Y, Ye R, Lee AS. Role of the unfolded protein response regulator GRP78/BiP in development, cancer, and neurological disorders. Antioxid. Redox Signaling. 2009;11(9):2307–2316. doi:10.1089/ars.2009.2485
   PubMed Web of Science ®Google Scholar
• Cerezo M, Rocchi S. New anti-cancer molecules targeting HSPA5/BIP to induce endoplasmic reticulum stress, autophagy and apoptosis. Autophagy. 2017;13(1):216–217. doi:10.1080/15548627.2016.1246107
   PubMed Web of Science ®Google Scholar
• Watanabe D, Kimura T, Yamashita A, Minowa T, Miura K, Mizushima A. The influence of androgen deprivation therapy on Hip geometric properties and bone mineral density in Japanese men with prostate cancer and its relationship with the visceral fat accumulation. Aging Male. 2020;23(5):1158–1164. doi:10.1080/13685538.2020.1713741
   PubMed Web of Science ®Google Scholar
• Nadiminty N, Tummala R, Lou W, et al. MicroRNA let-7c Is downregulated in prostate cancer and suppresses prostate cancer growth. PLoS One. 2012;7(3):e32832. doi:10.1371/journal.pone.0032832
   PubMed Web of Science ®Google Scholar
• Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci. 2005;102(39):13944–13949. doi:10.1073/pnas.0506654102
   PubMed Web of Science ®Google Scholar
• Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC. Coordinate Suppression of ERBB2 and ERBB3 by Enforced Expression of Micro-RNA miR-125a or miR-125b*. J Biol Chem. 2007;282(2):1479–1486. doi:10.1074/jbc.M609383200
   PubMed Web of Science ®Google Scholar
• Rowley KHM, Mason MD. The aetiology and pathogenesis of prostate cancer. Clin Oncol. 1997;9(4):213–218. doi:10.1016/S0936-6555(97)80003-9
   Google Scholar
• Chen H, Zhou L, Wu X, et al. The PI3K/AKT pathway in the pathogenesis of prostate cancer. Front Biosci. 2016;21(5):1084–1091. doi:10.2741/4443
   PubMed Web of Science ®Google Scholar
• Cumberbatch MGK, Noon AP. Epidemiology, aetiology and screening of bladder cancer. Transl Androlo Urol. 2019;8(1):5–11. doi:10.21037/tau.2018.09.11
   PubMed Web of Science ®Google Scholar
• Liu J-M, Shen C-Y, Lau WCY, et al. Association between androgen deprivation therapy and risk of dementia in men with prostate cancer. Cancers. 2021;13(15):3861. doi:10.3390/cancers13153861
   PubMed Web of Science ®Google Scholar
• Sun M, Wang Y, Sundquist J, Sundquist K, Ji J. The association between cancer and dementia: a national cohort study in Sweden. original research. Front Oncol. 2020;10. doi:10.3389/fonc.2020.00073
   PubMed Web of Science ®Google Scholar
• Jhan JH, Yang YH, Chang YH, Guu SJ, Tsai CC. Hormone therapy for prostate cancer increases the risk of Alzheimer’s disease: a nationwide 4-year longitudinal cohort study. Aging Male. 2017;20(1):33–38. doi:10.1080/13685538.2016.1271782
   PubMed Web of Science ®Google Scholar
• Achard V, Ceyzériat K, Tournier BB, Frisoni GB, Garibotto V, Zilli T. Biomarkers to evaluate androgen deprivation therapy for prostate cancer and risk of Alzheimer’s disease and neurodegeneration: old drugs, new concerns. Review. Front Oncol. 2021;11. doi:10.3389/fonc.2021.734881
   Web of Science ®Google Scholar
• Qian C, Yang C, Lu M, et al. Activating AhR alleviates cognitive deficits of Alzheimer’s disease model mice by upregulating endogenous Aβ catabolic enzyme Neprilysin. Theranostics. 2021;11(18):8797–8812. doi:10.7150/thno.61601
   PubMed Web of Science ®Google Scholar
• Marr RA, Spencer BJ. NEP-like endopeptidases and Alzheimer’s disease [corrected]. Current Alzheimer Res. 2010;7(3):223–229. doi:10.2174/156720510791050849
   PubMed Web of Science ®Google Scholar
• Shim M, Bang WJ, Oh CY, Lee YS, Cho JS. Androgen deprivation therapy and risk of cognitive dysfunction in men with prostate cancer: is there a possible link? Prostate international. Mar. 2022;10(1):68–74. doi:10.1016/j.prnil.2021.02.002
   Google Scholar
• Tripathi PN, Srivastava P, Sharma P, et al. Biphenyl-3-oxo-1,2,4-triazine linked piperazine derivatives as potential cholinesterase inhibitors with anti-oxidant property to improve the learning and memory. Bioorg Chem. 2019;85:82–96. doi:10.1016/j.bioorg.2018.12.017
   PubMed Web of Science ®Google Scholar
• Srivastava P, Tripathi PN, Sharma P, et al. Design and development of some phenyl benzoxazole derivatives as a potent acetylcholinesterase inhibitor with antioxidant property to enhance learning and memory. Eur J Med Chem. 2019;163:116–135. doi:10.1016/j.ejmech.2018.11.049
   PubMed Web of Science ®Google Scholar
• Shim M, Bang WJ, Oh CY, et al. Risk of dementia and Parkinson’s disease in patients treated with androgen deprivation therapy using gonadotropin-releasing hormone agonist for prostate cancer: a nationwide population-based cohort study. PLoS One. 2020;15(12):e0244660. doi:10.1371/journal.pone.0244660
   PubMed Web of Science ®Google Scholar
• Jayadevappa R, Chhatre S, Malkowicz SB, Parikh RB, Guzzo T, Wein AJ. Association between androgen deprivation therapy use and diagnosis of dementia in men with prostate cancer. JAMA network open. 2019;2(7):e196562. doi:10.1001/jamanetworkopen.2019.6562
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Laughlin GA. Endogenous and Exogenous Estrogen, Cognitive Function, and Dementia in Postmenopausal Women: Evidence from Epidemiologic Studies and Clinical Trials. © Thieme Medical Publishers; 2009:275–282.
   Google Scholar
• Beauchet O. Testosterone and cognitive function: current clinical evidence of a relationship. European J Endocrinol. 2006;155(6):773–781. doi:10.1530/eje.1.02306
   PubMed Web of Science ®Google Scholar
• Kenny AM, Bellantonio S, Gruman CA, Acosta RD, Prestwood KM. Effects of transdermal testosterone on cognitive function and health perception in older men with low bioavailable testosterone levels. J Gerontol Ser A. 2002;57(5):M321–5. doi:10.1093/gerona/57.5.m321
   PubMed Web of Science ®Google Scholar
• Jiménez-Rubio G, Herrera-Pérez JJ, Hernández O, Martínez-Mota L. Relationship between androgen deficiency and memory impairment in aging and Alzheimer’s disease. Actas Espanolas de Psiquiatria. 2017;45(5):227–247.
   PubMed Web of Science ®Google Scholar
• Zachariae R, Buus S, Buus S, et al. Cognitive impairment and associations with structural brain networks, endocrine status, and risk genotypes in patients with newly diagnosed prostate cancer referred to androgen-deprivation therapy. Cancer. 2021;127(9):1495–1506. doi:10.1002/cncr.33387
   PubMed Web of Science ®Google Scholar
• Gallus S, Foschi R, Talamini R, et al. Risk factors for prostate cancer in men aged less than 60 years: a case–control study from Italy. Urology. 2007;70(6):1121–1126. doi:10.1016/j.urology.2007.07.020
   PubMed Web of Science ®Google Scholar
• Reiss A, Saeedullah U, Grossfeld D, Glass A, Pinkhasov A, Katz AE. Prostate cancer treatment and the relationship of androgen deprivation therapy to cognitive function. Clin Transl Oncol. 2021;3:1–9.
   Google Scholar
• Robinson D, Garmo H, Van Hemelrijck M, et al. Androgen deprivation therapy for prostate cancer and risk of dementia. BJU Int. 2019;124(1):87–92. doi:10.1111/bju.14666
   PubMed Web of Science ®Google Scholar
• Arya A, Ahmad H, Khandelwal K, Agrawal S, Dwivedi A. Novel multifunctional nanocarrier-mediated codelivery for targeting and treatment of prostate cancer. InNanomat Drug Deliv Ther. 2019;3:185–224.
   Google Scholar
• Perry G, Cortezon-Tamarit F, Pascu S. Detection and monitoring prostate specific antigen using nanotechnology approaches to biosensing. Front Chem Sci Eng. 2019;14. doi:10.1007/s11705-019-1846-8
   Web of Science ®Google Scholar
• Nevedomskaya E, Baumgart SJ, Haendler B. Recent advances in prostate cancer treatment and drug discovery. Int J Mol Sci. 2018;19(5):1359. doi:10.3390/ijms19051359
   PubMed Web of Science ®Google Scholar
• Nagesh PK, Chowdhury P, Hatami E, et al. Cross-linked polyphenol-based drug nano-self-assemblies engineered to blockade prostate cancer senescence. ACS Appl Mater Interfaces. 2019;11(42):38537–38554. doi:10.1021/acsami.9b14738
   PubMed Web of Science ®Google Scholar
• Zheng G, Patolsky F, Cui Y, Wang WU, Lieber CM. Multiplexed electrical detection of cancer markers with nanowire sensor arrays. Nature Biotechnol. 2005;23(10):1294–1301. doi:10.1038/nbt1138
   PubMed Web of Science ®Google Scholar
• Li X, Li W, Yang Q, et al. Rapid and quantitative detection of prostate specific antigen with a quantum dot nanobeads-based immunochromatography test strip. ACS Appl Mater Interfaces. 2014;6(9):6406–6414. doi:10.1021/am5012782
   PubMed Web of Science ®Google Scholar
• Yu X, Munge B, Patel V, et al. Carbon nanotube amplification strategies for highly sensitive immunodetection of cancer biomarkers. J Am Chem Soc. 2006;128(34):11199–11205. doi:10.1021/ja062117e
   PubMed Web of Science ®Google Scholar
• Song E-Q, Hu J, Wen C-Y, et al. Fluorescent-magnetic-biotargeting multifunctional nanobioprobes for detecting and isolating multiple types of tumor cells. ACS nano. 2011;5(2):761–770. doi:10.1021/nn1011336
   PubMed Web of Science ®Google Scholar
• Koo KM, Dey S, Trau M. Amplification-free multi-RNA-Type profiling for cancer risk stratification via alternating current electrohydrodynamic nanomixing. Small. 2018;14(17):1704025. doi:10.1002/smll.201704025
   Web of Science ®Google Scholar
• Xu S, Liu Y, Wang T, Li J. Positive potential operation of a cathodic electrogenerated chemiluminescence immunosensor based on luminol and graphene for cancer biomarker detection. Anal. Chem. 2011;83(10):3817–3823. doi:10.1021/ac200237j
   PubMed Web of Science ®Google Scholar
• Koo KM, Mainwaring PN, Tomlins SA, Trau M. Merging new-age biomarkers and nanodiagnostics for precision prostate cancer management. Nat Rev Urol. 2019;16(5):302–317. doi:10.1038/s41585-019-0178-2
   PubMed Web of Science ®Google Scholar
• Fabris L, Ceder Y, Chinnaiyan AM, et al. The potential of microRNAs as prostate cancer biomarkers. Europ Urol. 2016;70(2):312–322. doi:10.1016/j.eururo.2015.12.054
   PubMed Web of Science ®Google Scholar
• Prensner JR, Iyer MK, Sahu A, et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nature Genet. 2013;45(11):1392–1398. doi:10.1038/ng.2771
   PubMed Web of Science ®Google Scholar
• Shah RB, Chinnaiyan AM. The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications. Adv Anatomic Pathol. 2009;16(3):145–153. doi:10.1097/PAP.0b013e3181a12da7
   PubMed Web of Science ®Google Scholar
• Kumar-Sinha C, Kalyana-Sundaram S, Chinnaiyan AM. Landscape of gene fusions in epithelial cancers: seq and ye shall find. Genome Med. 2015;7(1):129. doi:10.1186/s13073-015-0252-1
   PubMedGoogle Scholar
• Edwards PA. Fusion genes and chromosome translocations in the common epithelial cancers. J Pathol. 2010;220(2):244–254. doi:10.1002/path.2632
   PubMed Web of Science ®Google Scholar
• Haile S, Sadar MD. Androgen receptor and its splice variants in prostate cancer. Cell. Mol. Life Sci. 2011;68(24):3971–3981. doi:10.1007/s00018-011-0766-7
   PubMed Web of Science ®Google Scholar
• Ware KE, Garcia-Blanco MA, Armstrong AJ, Dehm SM. Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer. Endocrine Related Cancer. 2014;21(4):T87–T103. doi:10.1530/ERC-13-0470
   PubMed Web of Science ®Google Scholar
• Phin S, Moore M, Cotter P. Genomic rearrangements of PTEN in prostate cancer. Review. Front Oncol. 2013;3:3. doi:10.3389/fonc.2013.00240
   PubMedGoogle Scholar
• Lotan TL, Heumann A, Rico SD, et al. PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort. Oncotarget. 2017;8(39):65566. doi:10.18632/oncotarget.19217
   PubMedGoogle Scholar
• Punnoose EA, Ferraldeschi R, Szafer-Glusman E, et al. PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients. Br J Cancer. 2015;113(8):1225–1233. doi:10.1038/bjc.2015.332
   PubMed Web of Science ®Google Scholar
• Day JR, Jost M, Reynolds MA, Groskopf J, Rittenhouse H. PCA3: from basic molecular science to the clinical lab. Cancer Lett. 2011;301(1):1–6. doi:10.1016/j.canlet.2010.10.019
   PubMed Web of Science ®Google Scholar
• Ferreira LB, Palumbo A, de Mello KD, et al. PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling. BMC Cancer. 2012;12(1):507. doi:10.1186/1471-2407-12-507
   PubMedGoogle Scholar
• Wade CA, Kyprianou N. Profiling prostate cancer therapeutic resistance. Int J Mol Sci. 2018;19(3):904. doi:10.3390/ijms19030904
   PubMed Web of Science ®Google Scholar
• Marzouk S, Naglie G, Tomlinson G, et al. Impact of androgen deprivation therapy on self-reported cognitive function in men with prostate cancer. J Urol. 2018;200(2):327–334. doi:10.1016/j.juro.2018.02.073
   PubMed Web of Science ®Google Scholar
• Rai SN, Singh C, Singh A, Singh MP, Singh BK. Mitochondrial Dysfunction: a Potential Therapeutic Target to Treat Alzheimer’s Disease. Mol Neurobiol. 2020;57(7):3075–3088. doi:10.1007/s12035-020-01945-y
   PubMed Web of Science ®Google Scholar
• Rai SN, Zahra W, Birla H, Singh SS, Singh SP. Commentary: Mild endoplasmic reticulum stress ameliorates lpopolysaccharide-induced neuroinflammation and cognitive impairment via regulation of microglial polarization. Front Aging Neurosci. 2018;10:192. Published. doi:10.3389/fnagi.2018.00192
   PubMed Web of Science ®Google Scholar
• Nead KT, Gaskin G, Chester C, Swisher-McClure S, Leeper NJ, Shah NH. Association between androgen deprivation therapy and risk of dementia. JAMA Oncol. 2017;3(1):49–55. doi:10.1001/jamaoncol.2016.3662
   PubMed Web of Science ®Google Scholar
• Adeloye D, David RA, Aderemi AV, et al. An estimate of the incidence of prostate cancer in Africa: a systematic review and meta-analysis. PLoS One. 2016;11(4):e0153496. doi:10.1371/journal.pone.0153496
   PubMed Web of Science ®Google Scholar
• Wang G, Zhao D, Spring DJ, DePinho RA. Genetics and biology of prostate cancer. Genes Dev. 2018;32(17–18):1105–1140. doi:10.1101/gad.315739.118
   PubMed Web of Science ®Google Scholar
• Nguyen PL, Alibhai SMH, Basaria S, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Europ Urol. 2015;67(5):825–836. doi:10.1016/j.eururo.2014.07.010
   PubMed Web of Science ®Google Scholar
• Aurilio G, Cimadamore A, Mazzucchelli R, et al. Androgen receptor signaling pathway in prostate cancer: from genetics to clinical applications. Cells. 2020;9(12):2653. doi:10.3390/cells9122653
   PubMed Web of Science ®Google Scholar